P05.org

Latest — 12 May 2026

Rights Reacquisition: Buyer Archetypes, Royalty Stack Mechanics, and the Asymmetric Pricing of Returned Pharmaceutical Assets

A pharmaceutical right, once licensed, comes home through a dozen distinct mechanisms operated by five distinct buyer archetypes. The same legal instrument (an Asset Purchase Agreement, a Termination Agreement, a contractual reversion clause) means very different things depending on whether a Phase-3-failed asset is being salvaged by its original developer,

More issues

Waterfall Disputes in Stacked Royalty Deals: When Multiple Holders Go to War Over the Same Revenue Stream

In April 2022, a Texas jury needed two hours to decide that Daiichi Sankyo owed Seagen $41.8 million in back royalties on Enhertu — plus an 8% running rate on all future US sales of what was already a multi-billion dollar oncology franchise. Three years later, the Federal Circuit reversed

The Weekly Term Sheet (2026-W19)

W19 at a glance Window: Sun May 3 – Fri May 8, 2026. ~$17.95B committed deal value + up to $5.5B contingent + ~$3.2B fresh biotech equity / structured capital. Headline events: $6.7B Merck/Terns close (Tue); $4.1B Angelini/Catalyst (Thu); $1.05B Roche/PathAI (Thu); $1.0B Phoenix

The Deuterium Problem: When a Hydrogen Swap Becomes a Royalty Dispute

How a royalty fund and a pharma company ended up in arbitration over whether deutivacaftor is the same compound as ivacaftor — and what it means for the pharmaceutical royalty market

Company of the week: Immunocore

Immunocore Holdings plc is an Oxfordshire, UK-based commercial-stage biotechnology company developing a novel class of TCR bispecific immunotherapies branded ImmTAX (Immune mobilizing monoclonal TCRs Against X disease). The company trades on Nasdaq under the ticker IMCR and, as of late April 2026, carries a market capitalisation in the $1.5–

Fund of the week: Vie Ventures

Fund Snapshot Firm Vie Ventures Vehicle Immunology & Autoimmune (I&A) Fund LP Established July 9, 2025 (public launch) Headquarters 245 Main St, Floor 2, Cambridge, MA 02142 Strategy Series B and C equity into private biotech companies developing therapies for autoimmune and immune-mediated diseases Structure Closed-end venture fund,

When Does the Money Stop? Modeling Royalty Stream Expiry in Pharmaceutical Transactions

The single most consequential variable in any royalty valuation is the terminal date — the point at which cash flows cease. Getting this wrong by even two years can shift an asset's net present value by 15–25%. Yet the mechanics of royalty expiry remain among the least well-understood

Insolvency Liens in Pharma Royalty Transactions: The Risk That Reshapes Deal Structure

When Clearside Biomedical filed for Chapter 11 protection in November 2025, equity holders quickly zeroed in on a detail buried in the company's pre-petition filings: a September 2025 amendment to its royalty agreement with HealthCare Royalty Partners had allegedly waived a contingent $12.5 million payment, nearly five

Buying More of the Same Royalty: Top-Ups, Tier Extensions and the Anatomy of an Amendment

Royalty financing rarely ends at signing. The cleanest recent illustration of why is the AnaptysBio/Sagard relationship on Jemperli. Three documents, three years apart, restructure who owns what slice of GSK's payment obligation, and the legal architecture is doing real economic work. This piece walks through the documents,

The Weekly Term Sheet (2026-W18)

W18 at a glance Window total: ~US$25.0B in committed cash and equity consideration, plus US$8.6B in assumed debt (Sun Pharma / Organon), plus up to ~US$10.4B in disclosed contingent biobucks (max-case milestones and CVRs, undiscounted). The committed-versus-contingent split matters because most aggregate deal-value figures published

About

P05.org

Weekly structural analysis on pharmaceutical royalty financing. Deal mechanics, legal events, fund positioning, primary sources.

More issues

Subscribe to P05.org